Back to Journals » Drug Design, Development and Therapy » Volume 15

The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data

Authors Napolitano M, Fabbrocini G, Ruggiero A, Marino V, Nocerino M, Patruno C

Received 10 December 2020

Accepted for publication 1 March 2021

Published 10 March 2021 Volume 2021:15 Pages 1135—1147

DOI https://doi.org/10.2147/DDDT.S240866

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Georgios D. Panos


Maddalena Napolitano,1 Gabriella Fabbrocini,2 Angelo Ruggiero,2 Vincenzo Marino,2 Mariateresa Nocerino,2 Cataldo Patruno3

1Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy; 2Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 3Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy

Correspondence: Maddalena Napolitano
Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy
Tel +39 0817462439
Email [email protected]

Abstract: Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease that predominantly affects children. However, it can persist in adulthood and/or start at older ages. Both dysfunction of the epidermal barrier and immune dysregulation are known to play a role in the pathogenesis of AD. In the last years, numerous studies showed that Janus kinase (JAK) enzymes have a key role in AD pathogenesis. Therefore, oral and topical JAK inhibitors are new emerging treatments for AD. We report the data relating to abrocitinib, an oral JAK1 inhibitor. For this purpose, we examined articles already published concerning, in particular, concluded clinical trials. Furthermore, we also report the design of current ongoing clinical trials. The search was carried out considering the main search engines relating to medical literature and clinical trials. From all the data we collected, abrocitinib proved to be an effective drug in significantly reducing the severity of moderate-to-severe AD when compared to placebo. Furthermore, the efficacy was similar to other well-established treatment for AD, such as dupilumab. Adverse events were generally mild; indeed, the drug was definitively suspended only in few patients.

Keywords: atopic dermatitis, abrocitinib, JAK inhibitors, JAK-STAT

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]